Alternatively, it may be preferential to deliver anti-CD40 at a lower dose via subcutaneous injection to target specific tumor deposits, draining lymph nodes, or vaccine-specific sites, which is an approach we are currently exploring in a melanoma clinical trial at our institution. This evidence concerns the gene CD40 and neoplasm.